Financial reports
10-K
2023 FY
Annual report
7 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
30 Mar 22
Current reports
8-K
Entry into a Material Definitive Agreement
12 Apr 24
8-K
Entry into a Material Definitive Agreement
16 Feb 24
8-K
Departure of Directors or Certain Officers
25 Jan 24
8-K
Regulation FD Disclosure
5 Jan 24
8-K
Savara Announces Pricing of $80 Million Underwritten Offering of Common
13 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Regulation FD Disclosure
8 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
30 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Entry into a Material Definitive Agreement
2 Mar 23
Registration and prospectus
S-8
Registration of securities for employees
7 Mar 24
424B5
Prospectus supplement for primary offering
13 Jul 23
S-8
Registration of securities for employees
16 Jun 23
S-8
Registration of securities for employees
30 Mar 23
S-8
Registration of securities for employees
20 Jan 23
S-8
Registration of securities for employees
21 Nov 22
S-8
Registration of securities for employees
30 Mar 22
S-8
Registration of securities for employees
6 Jul 21
S-3
Shelf registration
6 Jul 21
424B5
Prospectus supplement for primary offering
12 Mar 21
Proxies
PRE 14A
Preliminary proxy
12 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
19 Apr 22
DEF 14A
Definitive proxy
19 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
PRE 14A
Preliminary proxy
16 Apr 21
DEFA14A
Additional proxy soliciting materials
8 May 20
DEFA14A
Additional proxy soliciting materials
15 Apr 20
Other
EFFECT
Notice of effectiveness
19 Jul 21
CORRESP
Correspondence with SEC
14 Jul 21
UPLOAD
Letter from SEC
12 Jul 21
EFFECT
Notice of effectiveness
30 Apr 20
CORRESP
Correspondence with SEC
27 Apr 20
UPLOAD
Letter from SEC
24 Apr 20
CT ORDER
Confidential treatment order
30 Aug 18
EFFECT
Notice of effectiveness
16 Jul 18
CORRESP
Correspondence with SEC
10 Jul 18
UPLOAD
Letter from SEC
9 Jul 18
Ownership
4
Anne Erickson
23 Apr 24
SC 13D/A
Bain Capital Life Sciences Fund II, L.P.
12 Apr 24
3
Anne Erickson
29 Mar 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
Zambon SpA
14 Feb 24
SC 13G
PRUDENTIAL FINANCIAL INC
13 Feb 24
SC 13G/A
CAXTON CORP
13 Feb 24
SC 13G
JENNISON ASSOCIATES LLC
8 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
SC 13G/A
Farallon Capital Partners, L.P.
1 Feb 24